Navitoclax-piperazine

• CAT Number: I017193
• CAS Number: 2143096-93-7
• Molecular Formula: C₄₇H₅₆ClF₃N₆O₅S₃
• Molecular Weight: 973.63
• Purity: ≥95%
• Target: PROTAC
• IUPAC Name: 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-1-phenylsulfanyl-4-piperazin-1-ylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide
• InChI: 1S/C47H56ClF3N6O5S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-56-26-28-57(29-27-56)39-14-10-35(11-15-39)45(58)54-65(61,62)41-16-17-43(44(30-41)64(59,60)47(49,50)51)53-38(19-23-55-24-21-52-22-25-55)33-63-40-6-4-3-5-7-40/h3-17,30,38,52-53H,18-29,31-33H2,1-2H3,(H,54,58)/t38-/m1/s1
• InChIKey: CRPNZDFOWRFBLZ-KXQOOQHDSA-N
• SMILES: CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCNCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C

Navitoclax-piperazine (Cat.No:I017193) is a potent and selective inhibitor of B-cell lymphoma 2 (Bcl-2) proteins. It is used in the treatment of various types of cancer, including chronic lymphocytic leukemia and small cell lung cancer. Navitoclax-piperazine works by blocking the anti-apoptotic proteins in cancer cells, leading to cell death. It is being investigated as a promising therapeutic option in oncology.

Reference

[1]. Sajid Khan, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med 25, 1938–1947 (2019).